SCHEMBL166597

SCHEMBL166597

O=C(O)c1nc(Cl)c2sccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 1/20 0.46
DYRK1A Q13627 1/20 0.46
AXL P30530 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ADORA2A P29274 8/20 0.39
ADORA1 P30542 6/20 0.39
SPR P35270 2/20 0.38
MAPT P10636 3/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.37
ADORA2B P29275 1/20 0.36
CSNK2A1 P68400 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164536 0.78 NPC1 (0.49) AXLMKNK1MKNK2RAB9ANPC1
SCHEMBL163775 0.77 KMT2A (0.42) RAB9ANPC1NPSR1CTDSP1RXFP1
SCHEMBL29720665 0.75 HTR2C (0.44) CDK9DYRK1AADORA2ASPRKMT2A
SCHEMBL26042355 0.75 HTR2C (0.44) CDK9DYRK1AADORA2ASPRKMT2A
SCHEMBL16505979 0.74 CDK9 (0.48) CDK9DYRK1AAXLMKNK1MKNK2
SCHEMBL31462939 0.72 ADORA2A (0.58) CDK9DYRK1AAXLMKNK1MKNK2
SCHEMBL55563 0.72 ADORA2A (0.58) CDK9DYRK1AAXLMKNK1MKNK2
SCHEMBL6215714 0.72 ADORA2A (0.69) ADORA2AADORA1ADORA2BALOX15
SCHEMBL22694433 0.70 MAOA (0.47) CDK9DYRK1ANPSR1RXFP1MAPT
SCHEMBL11090852 0.70 ADORA2A (0.43) CDK9DYRK1AAXLMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3036229-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2016-06-29 EP disclosed
WO-2015025026-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2015-02-26 WO disclosed
US-20130317045-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-11-28 US disclosed
EP-2611812-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030894-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317045-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF JAK2, JAK3, TYK2 CDK9 34/4885DYRK1A 511/4885AXL 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.